Critical Outcome T (COTQF) Downgraded by Zacks Investment Research to Sell

Critical Outcome T (OTCMKTS:COTQF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

According to Zacks, “Cotinga Pharmaceuticals Inc. is a clinical-stage pharmaceutical company which uses proprietary artificial intelligence technologies to develop innovative therapies to treat a wide spectrum of cancers. The Company’s CHEMSAS(R) platform evaluates biological activity from molecular structures, allowing the Company to build a pipeline of potential drug candidates with predictive accuracy and expediency when compared to traditional development methods. Cotinga Pharmaceuticals Inc., formerly known as Critical Outcome Technologies Inc., is based in Boston, Massachusetts. “

Separately, ValuEngine raised Critical Outcome T from a “strong sell” rating to a “sell” rating in a research note on Friday.

Critical Outcome T (OTCMKTS COTQF) traded down $0.00 on Tuesday, reaching $0.59. The company had a trading volume of 200 shares, compared to its average volume of 450. Critical Outcome T has a 1 year low of $0.59 and a 1 year high of $4.80.

Critical Outcome T (OTCMKTS:COTQF) last released its earnings results on Friday, December 29th. The company reported ($0.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at

Critical Outcome T Company Profile

Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The company’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.

Get a free copy of the Zacks research report on Critical Outcome T (COTQF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Critical Outcome T Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T and related companies with's FREE daily email newsletter.

Leave a Reply